The UAE will establish a localized manufacturing and clinical pathway for umbilical cord stem cell therapies for the first time.
Abu Dhabi Biobank has partnered with Human Life CORD Japan Inc. to localize the development of umbilical cord-derived stem cell therapies in the UAE, marking a major step in the country’s push toward advanced regenerative healthcare.
The collaboration, backed by the Department of Health Abu Dhabi and global health company M42, aims to establish the UAE’s first localized manufacturing and clinical development pathway for Umbilical Cord Mesenchymal Stem Cell (UC-MSC) therapies.
The initiative will create an integrated ecosystem covering biospecimen collection, cryogenic storage, research, manufacturing, and clinical application, allowing stem cell therapies to move more efficiently from laboratory development to patient treatment.
Focus on Diabetes and Chronic Disease Treatment
Umbilical cord-derived stem cell therapies are drawing increasing global attention because of their ability to regulate immune responses, reduce inflammation, and support tissue repair. Researchers believe these therapies could play a major role in treating chronic illnesses where conventional medicine often focuses primarily on symptom management.
The Abu Dhabi initiative will initially focus on conditions such as diabetes, musculoskeletal disorders, and age-related diseases, all of which continue to place growing pressure on healthcare systems across the MENA region.
Officials said the project reflects a broader transition in the UAE healthcare model, shifting from reactive treatment toward prevention-driven and precision-based medicine.
According to Asma AlMannaei, the initiative supports the country’s long-term effort to accelerate personalized therapies while positioning Abu Dhabi as a global center for advanced biobanking and medical research.
UAE to Build Local Manufacturing Capability
A central element of the partnership is the localization of stem cell manufacturing capabilities inside the UAE, reducing reliance on imported therapies and creating infrastructure aligned with regional healthcare needs.
Abu Dhabi Biobank will contribute advanced public cord blood banking systems, automated cryogenic storage infrastructure, and integrated genomic and clinical data platforms to support clinical research and regulatory processes.
Meanwhile, Human Life CORD will provide expertise in stem cell isolation, expansion technologies, and quality control systems, alongside a portfolio of therapies already undergoing mid- and late-stage clinical development in Japan.
Masamitsu Harata said the partnership would allow therapies validated internationally to be manufactured closer to regional patients while adapting production to local healthcare priorities.
Strengthening UAE-Japan Scientific Collaboration
Industry observers view the agreement as part of a wider scientific and healthcare collaboration between the UAE and Japan, particularly in sectors tied to biotechnology, longevity research, and advanced medicine.
The partnership also aligns with Abu Dhabi’s broader strategy to expand its life sciences sector and attract high-value biomedical research into the emirate.
As chronic disease rates continue to rise across the Gulf region, regenerative medicine is increasingly being positioned not only as a healthcare innovation field but as a long-term economic and scientific growth sector.
Conclusion
The stem cell initiative signals a deeper structural shift in how the UAE is approaching healthcare development. Rather than limiting its role to healthcare consumption, Abu Dhabi is building the infrastructure required to participate directly in advanced therapy research, manufacturing, and clinical innovation.
The long-term significance may extend beyond a single treatment category. It reflects an attempt to position the UAE as a regional producer of next-generation medical technologies rather than solely a destination for imported care.
Source: KT
Read more news, and follow us on Instagram
